Personalized tumor-loaded monocyte-derived dendritic cell vaccination in combination with atezolizumab as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC): phase Ib-II VENEZOLUNG trial.
Saved in:
| Title: | Personalized tumor-loaded monocyte-derived dendritic cell vaccination in combination with atezolizumab as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC): phase Ib-II VENEZOLUNG trial. |
|---|---|
| Authors: | Gonzalez-Cao M; Instituto Oncologico Dr Rosell, Dexeus University Hospital, Barcelona, Spain mgonzalezcao@oncorosell.com., Sisteré-Oró M; Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain., Moran T; Medical Oncology Department, Catalan Institute of Oncology, Badalona, Spain., Reguart N; Medical Oncology Department, Hospital Clinic de Barcelona, Barcelona, Spain., Cabezon R; Immunology Department, Hospital Clinic de Barcelona, FRCB-IDIBAPS, UB, Barcelona, Spain., Aguilar Hernández A; Instituto Oncologico Dr Rosell, Dexeus University Hospital, Barcelona, Spain., Roman R; Instituto Oncologico Dr Rosell and PangaeaOncology Lab, Dexeus University Hospital, Barcelona, Spain., Molina-Vila MA; Instituto Oncologico Dr Rosell and PangaeaOncology Lab, Dexeus University Hospital, Barcelona, Spain., Birgin K; Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain., Domenjo-Vila E; Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain., Piqué G; Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain., Lozano M; Apheresis Unit, IDIBAPS, Hospital Clinic de Barcelona, Barcelona, Spain., Charry P; Apheresis Unit, IDIBAPS, Hospital Clinic de Barcelona, Barcelona, Spain., Reyes R; Instituto Oncologico Dr Rosell, Dexeus University Hospital, Barcelona, Spain.; Instituto Oncologico Dr Rosell, Quirón Teknon Hospital, Barcelona, Spain., Moya I; Instituto Oncologico Dr Rosell, Dexeus University Hospital, Barcelona, Spain.; Instituto Oncologico Dr Rosell, Hospital Universitari General de Catalunya, Sant Cugat, Spain., Cirera L; Instituto Oncologico Dr Rosell, Hospital Universitari Sagrat Cor, Barcelona, Spain., Esparre C; Instituto Oncologico Dr Rosell, Dexeus University Hospital, Barcelona, Spain., Drozdowskyj A; Instituto Oncologico Dr Rosell, Dexeus University Hospital, Barcelona, Spain., Martínez Pérez E; Instituto Oncologico Dr Rosell and PangaeaOncology Lab, Dexeus University Hospital, Barcelona, Spain., Rosell R; Instituto Oncologico Dr Rosell, Dexeus University Hospital, Barcelona, Spain., Juan M; Immunology Department, Hospital Clinic de Barcelona, FRCB-IDIBAPS, UB, Barcelona, Spain., Meyerhans A; Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain.; ICREA, Barcelona, Spain., Benitez-Ribas D; Immunology Department, Hospital Clinic de Barcelona, FRCB-IDIBAPS, UB, Barcelona, Spain. |
| Source: | Journal for immunotherapy of cancer [J Immunother Cancer] 2026 Jul 24; Vol. 14 (7). Date of Electronic Publication: 2026 Jul 24. |
| Publication Type: | Journal Article; Clinical Trial, Phase II; Clinical Trial, Phase I |
| Journal Info: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
